MARKET

GBT

GBT

Global Blood
NASDAQ

Real-time Quotes | Nasdaq Last Sale

42.60
-0.90
-2.07%
After Hours: 41.88 -0.72 -1.69% 16:22 02/26 EST
OPEN
44.00
PREV CLOSE
43.50
HIGH
44.65
LOW
40.84
VOLUME
1.44M
TURNOVER
--
52 WEEK HIGH
83.69
52 WEEK LOW
36.49
MARKET CAP
2.63B
P/E (TTM)
-9.2046
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Wedbush Remains a Buy on Global Blood Therapeutics (GBT)
Wedbush analyst Liana Moussatos reiterated a Buy rating on Global Blood Therapeutics (GBT) today and set a price target of $138.00. The company's shares
SmarterAnalyst · 1d ago
AT&T, Expedia, Mattel, Urban Outfitters and More Thursday Afternoon Analyst Calls
247WallSt.com · 1d ago
Global Blood (GBT) Q4 Earnings Miss, Revenues Beat Estimates
Zacks.com · 1d ago
Sector Update: Health Care
MT Newswires · 1d ago
The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 24)
Benzinga · 1d ago
Raymond James Gives a Hold Rating to Global Blood Therapeutics (GBT)
In a report released yesterday, Danielle Brill from Raymond James assigned a Hold rating to Global Blood Therapeutics (GBT). The company's shares closed
SmarterAnalyst · 1d ago
--Analyst Actions: William Blair Downgrades Global Blood Therapeutics to Market Perform From Outperform
MT Newswires · 1d ago
Global Blood Therapeutics (GBT) Receives a Buy from Oppenheimer
In a report released today, Mark Breidenbach from Oppenheimer assigned a Buy rating to Global Blood Therapeutics (GBT), with a price target of $92.00. The
SmarterAnalyst · 1d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GBT. Analyze the recent business situations of Global Blood through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 20 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GBT stock price target is 84.63 with a high estimate of 138.00 and a low estimate of 45.00.
EPS
Institutional Holdings
Institutions: 421
Institutional Holdings: 68.24M
% Owned: 110.43%
Shares Outstanding: 61.80M
TypeInstitutionsShares
Increased
83
6.74M
New
105
-1.52M
Decreased
60
4.74M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.41%
Pharmaceuticals & Medical Research
-0.86%
Key Executives
President/Chief Executive Officer/Director
Ted Love
Chief Financial Officer
Jeffrey Farrow
Chief Human Resource Officer
Eric Fink
Chief Scientific Officer
Brian Cathers
Other
Jung Choi
Other
David Johnson
Other
Tricia Suvari
Lead Director/Independent Director
Mark Perry
Director
Deval Patrick
Independent Director
Willie Brown
Independent Director
Scott Morrison
Independent Director
Glenn Pierce
Independent Director
Philip Pizzo
Independent Director
Dawn Svoronos
Independent Director
Wendy Yarno
  • Dividends
  • Splits
  • Insider Activity
No Data
About GBT
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD). The Company is evaluating GBT440 in SCD in a Phase III clinical trial of GBT440 in adult and adolescent patients with SCD. GBT440 inhibits abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. The Company is also engaged in other research and development activities targeted towards hereditary angioedema (HAE). The Company's GBT440 is an investigational drug that increases hemoglobin's affinity for oxygen by binding to the alpha-chain of hemoglobin. GBT440 has been observed to keep a proportion of sickle hemoglobin (HbS), in its oxygenated state, where it cannot participate in polymerization.

Webull offers kinds of Global Blood Therapeutics Inc stock information, including NASDAQ:GBT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GBT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GBT stock methods without spending real money on the virtual paper trading platform.